Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor R115777 in human epithelial cancer cells

M. Caraglia, G. Giuberti, M. Marra, E. Di Gennaro, G. Facchini, F. Caponigro, R. V. Iaffeioli, A. Budillon, A. Abbruzzese

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Docetaxel (Taxotere, DTX) is a promoter of apoptosis in cancer cells. Since cytotoxic mechanisms of DTX are not yet fully understood, we have investigated the effects of DTX on apoptosis and ras->Erk-mediated signal transduction in human epidermoid KB, colon HT-29 and breast HCC1937 cancer cells. We have found that the exposure to 0.78 or 1.56 or 2.5 ng/ml DTX for 48 h induced apoptosis and growth inhibition in about 50 % of KB, HCC1937 and HT-29 cell population, respectively. In these experimental conditions, PARP and caspase 3 cleavage was also showed in all cell lines. KB and HCC1937 cells express a wild type p53 while HT-29 display a mutated form. Interestingly, we have found that DTX reduces the expression of mutated p53 in HT-29 and increases the expression of wild type in KB and HCC1937 cells. Moreover, DTX reduces ubiquitination of the wild type p53 in KB and HCC1937 cells and increases the ubiquitin-conjugated form of mutated p53 in HT-29 cells. Furthermore, exposure of cancer cells to DTX for 48 h increases the expression and activity of Ras and upregulates Raf-1 and the phosphorylated isoforms of Erk-1/2. On the bases of these data, we have hypothesized that the increased activity of the ras->erk-dependent pathway induced by DTX could be a protective signalling from the apoptosis caused by the drug. Therefore, we have used R115777, a farnesyl transferase inhibitor that inactivates ras, in combination with DTX. The combined treatment with DTX and R115777 resulted in a strong synergism in growth inhibition in the three cell lines. These data suggest the use of the combination in these therapeutic settings even if further experiments are required for the clinical translation.

Original languageEnglish
Pages (from-to)2566-2575
Number of pages10
JournalFrontiers in Bioscience
Volume10
Issue numberSUPPL. 2
Publication statusPublished - 2005

Fingerprint

docetaxel
tipifarnib
Transferases
KB Cells
Epithelial Cells
Cells
Apoptosis
HT29 Cells
Neoplasms
Cell Line
Ubiquitination
Growth
Ubiquitin
Caspase 3
Signal Transduction
Signal transduction
Protein Isoforms
Colon
Up-Regulation
Breast Neoplasms

Keywords

  • Apoptosis
  • Docetaxel
  • Epithelial Tumour Cells
  • Erk
  • Growth Inhibition
  • p53
  • R115777
  • Ras
  • Synergism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor R115777 in human epithelial cancer cells. / Caraglia, M.; Giuberti, G.; Marra, M.; Di Gennaro, E.; Facchini, G.; Caponigro, F.; Iaffeioli, R. V.; Budillon, A.; Abbruzzese, A.

In: Frontiers in Bioscience, Vol. 10, No. SUPPL. 2, 2005, p. 2566-2575.

Research output: Contribution to journalArticle

@article{d8d74b4268044ff0b448b1923d5d6603,
title = "Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor R115777 in human epithelial cancer cells",
abstract = "Docetaxel (Taxotere, DTX) is a promoter of apoptosis in cancer cells. Since cytotoxic mechanisms of DTX are not yet fully understood, we have investigated the effects of DTX on apoptosis and ras->Erk-mediated signal transduction in human epidermoid KB, colon HT-29 and breast HCC1937 cancer cells. We have found that the exposure to 0.78 or 1.56 or 2.5 ng/ml DTX for 48 h induced apoptosis and growth inhibition in about 50 {\%} of KB, HCC1937 and HT-29 cell population, respectively. In these experimental conditions, PARP and caspase 3 cleavage was also showed in all cell lines. KB and HCC1937 cells express a wild type p53 while HT-29 display a mutated form. Interestingly, we have found that DTX reduces the expression of mutated p53 in HT-29 and increases the expression of wild type in KB and HCC1937 cells. Moreover, DTX reduces ubiquitination of the wild type p53 in KB and HCC1937 cells and increases the ubiquitin-conjugated form of mutated p53 in HT-29 cells. Furthermore, exposure of cancer cells to DTX for 48 h increases the expression and activity of Ras and upregulates Raf-1 and the phosphorylated isoforms of Erk-1/2. On the bases of these data, we have hypothesized that the increased activity of the ras->erk-dependent pathway induced by DTX could be a protective signalling from the apoptosis caused by the drug. Therefore, we have used R115777, a farnesyl transferase inhibitor that inactivates ras, in combination with DTX. The combined treatment with DTX and R115777 resulted in a strong synergism in growth inhibition in the three cell lines. These data suggest the use of the combination in these therapeutic settings even if further experiments are required for the clinical translation.",
keywords = "Apoptosis, Docetaxel, Epithelial Tumour Cells, Erk, Growth Inhibition, p53, R115777, Ras, Synergism",
author = "M. Caraglia and G. Giuberti and M. Marra and {Di Gennaro}, E. and G. Facchini and F. Caponigro and Iaffeioli, {R. V.} and A. Budillon and A. Abbruzzese",
year = "2005",
language = "English",
volume = "10",
pages = "2566--2575",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor R115777 in human epithelial cancer cells

AU - Caraglia, M.

AU - Giuberti, G.

AU - Marra, M.

AU - Di Gennaro, E.

AU - Facchini, G.

AU - Caponigro, F.

AU - Iaffeioli, R. V.

AU - Budillon, A.

AU - Abbruzzese, A.

PY - 2005

Y1 - 2005

N2 - Docetaxel (Taxotere, DTX) is a promoter of apoptosis in cancer cells. Since cytotoxic mechanisms of DTX are not yet fully understood, we have investigated the effects of DTX on apoptosis and ras->Erk-mediated signal transduction in human epidermoid KB, colon HT-29 and breast HCC1937 cancer cells. We have found that the exposure to 0.78 or 1.56 or 2.5 ng/ml DTX for 48 h induced apoptosis and growth inhibition in about 50 % of KB, HCC1937 and HT-29 cell population, respectively. In these experimental conditions, PARP and caspase 3 cleavage was also showed in all cell lines. KB and HCC1937 cells express a wild type p53 while HT-29 display a mutated form. Interestingly, we have found that DTX reduces the expression of mutated p53 in HT-29 and increases the expression of wild type in KB and HCC1937 cells. Moreover, DTX reduces ubiquitination of the wild type p53 in KB and HCC1937 cells and increases the ubiquitin-conjugated form of mutated p53 in HT-29 cells. Furthermore, exposure of cancer cells to DTX for 48 h increases the expression and activity of Ras and upregulates Raf-1 and the phosphorylated isoforms of Erk-1/2. On the bases of these data, we have hypothesized that the increased activity of the ras->erk-dependent pathway induced by DTX could be a protective signalling from the apoptosis caused by the drug. Therefore, we have used R115777, a farnesyl transferase inhibitor that inactivates ras, in combination with DTX. The combined treatment with DTX and R115777 resulted in a strong synergism in growth inhibition in the three cell lines. These data suggest the use of the combination in these therapeutic settings even if further experiments are required for the clinical translation.

AB - Docetaxel (Taxotere, DTX) is a promoter of apoptosis in cancer cells. Since cytotoxic mechanisms of DTX are not yet fully understood, we have investigated the effects of DTX on apoptosis and ras->Erk-mediated signal transduction in human epidermoid KB, colon HT-29 and breast HCC1937 cancer cells. We have found that the exposure to 0.78 or 1.56 or 2.5 ng/ml DTX for 48 h induced apoptosis and growth inhibition in about 50 % of KB, HCC1937 and HT-29 cell population, respectively. In these experimental conditions, PARP and caspase 3 cleavage was also showed in all cell lines. KB and HCC1937 cells express a wild type p53 while HT-29 display a mutated form. Interestingly, we have found that DTX reduces the expression of mutated p53 in HT-29 and increases the expression of wild type in KB and HCC1937 cells. Moreover, DTX reduces ubiquitination of the wild type p53 in KB and HCC1937 cells and increases the ubiquitin-conjugated form of mutated p53 in HT-29 cells. Furthermore, exposure of cancer cells to DTX for 48 h increases the expression and activity of Ras and upregulates Raf-1 and the phosphorylated isoforms of Erk-1/2. On the bases of these data, we have hypothesized that the increased activity of the ras->erk-dependent pathway induced by DTX could be a protective signalling from the apoptosis caused by the drug. Therefore, we have used R115777, a farnesyl transferase inhibitor that inactivates ras, in combination with DTX. The combined treatment with DTX and R115777 resulted in a strong synergism in growth inhibition in the three cell lines. These data suggest the use of the combination in these therapeutic settings even if further experiments are required for the clinical translation.

KW - Apoptosis

KW - Docetaxel

KW - Epithelial Tumour Cells

KW - Erk

KW - Growth Inhibition

KW - p53

KW - R115777

KW - Ras

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=21344462168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344462168&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 2566

EP - 2575

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

IS - SUPPL. 2

ER -